Reported 2 days ago
Goldman Sachs has started coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) with a Buy rating, setting a target price of $125. The firm anticipates that Vykat XR, Soleno's leading treatment for Prader-Willi syndrome, will become a foundational therapy and believes that the recent stock pullback offers a favorable investment opportunity.
Source: YAHOO